Navigate Global Regulatory, Operational & Supply Complexities to Accelerate Patient Access, Harness Ethical Real-World Data, & Deliver Scalable Expanded Access Programs EAPs are evolving rapidly, ...
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company” or "Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX),, a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of ...
(MENAFN- GlobeNewsWire - Nasdaq) PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the“Company” or“Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs ...
Cognition Therapeutics (CGTX) announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する